Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

2021 ◽  
Author(s):  
Yong Ren ◽  
Houbo Jiang ◽  
Jiali Pu ◽  
Li Li ◽  
Jianbo Wu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Neurons ◽  
Molecular Features ◽  
Midbrain Dopaminergic Neurons

scholarly journals Editorial for the Special Issue “Animal Models of Parkinson’s Disease and Related Disorders”

2020 ◽  
Vol 21 (12) ◽  
pp. 4250
Author(s):  
Yuzuru Imai
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Animal Models ◽  
Dopaminergic Neurons ◽  
Neurodegenerative Disorder ◽  
Motor Dysfunction ◽  
Special Issue ◽  
Midbrain Dopaminergic Neurons ◽  
Age Dependent ◽  
Common Neurodegenerative Disorder

Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized by age-dependent motor dysfunction and degeneration of the midbrain dopaminergic neurons [...]

scholarly journals Parkinson's disease candidate gene prioritization based on expression profile of midbrain dopaminergic neurons

2010 ◽  
Vol 17 (1) ◽  
pp. 66 ◽  
Author(s):  
Shahrooz Vahedi ◽  
Mehrnoosh Rajabian ◽  
Arman Misaghian ◽  
Daniel Grbec ◽  
Horst H Simon ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Candidate Gene ◽  
Expression Profile ◽  
Dopaminergic Neurons ◽  
Gene Prioritization ◽  
Midbrain Dopaminergic Neurons ◽  
Disease Candidate Gene ◽  
Candidate Gene Prioritization

scholarly journals The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson’s disease

2021 ◽  
Author(s):  
Shamma Qarin ◽  
Sarah K Howlett ◽  
Joanne L Jones ◽  
Roger Barker
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pluripotent Stem Cells ◽  
Dopaminergic Neurons ◽  
Experimental Treatment ◽  
Safety And Efficacy ◽  
Cell Replacement ◽  
Midbrain Dopaminergic Neurons ◽  
Cell Source ◽  
Different Types

Dopaminergic (DA) cell replacement therapies are a promising experimental treatment for Parkinson’s disease and a number of different types of DA cell-based therapies have already been trialled in patients. To date the most successful have been allotransplants of foetal ventral midbrain but even then, the results have been inconsistent. This coupled to the ethical and logistical problems with using this tissue has meant that an alternative cell source has been sought of which human pluripotent stem cells (hPSC) sources have proven very attractive. Robust protocols for making mesencephalic DA progenitor cells from hPSC now exist and the first in-human clinical trials have or are about to start. However, while their safety and efficacy are well understood, relatively little is known about their immunogenicity and in this review, we briefly summarise this with reference mainly to the limited literature on human foetal dopaminergic cells.

Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson’s disease

2016 ◽  
Vol 614 ◽  
pp. 7-15 ◽  
Author(s):  
Ji Zhang ◽  
Beibei Yang ◽  
Hongbin Sun ◽  
Yan Zhou ◽  
Mengdi Liu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Neurons ◽  
Aquaporin 4 ◽  
Midbrain Dopaminergic Neurons

scholarly journals Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration

2014 ◽  
Vol 71 ◽  
pp. 345-358 ◽  
Author(s):  
Elpida Tsika ◽  
Meghna Kannan ◽  
Caroline Shi-Yan Foo ◽  
Dustin Dikeman ◽  
Liliane Glauser ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Neurons ◽  
Nuclear Abnormalities ◽  
Midbrain Dopaminergic Neurons ◽  
Conditional Expression
Sign in / Sign up

Export Citation Format

Share Document